• Citer

Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules.

par Awada, Ahmad ;Giacchetti, S;Gérard, B.;Eftekhary, P;Lucas, Catherine;de Valeriola, Dominique ;Poullain, M G;Soudon, J;Dosquet, C;Brillanceau, M-H;Giroux, B;Marty, Marianne;Bleiberg, Harry ;Calvo, F;Piccart-Gebhart, Martine
Référence Annals of oncology, 13, 12, page (1925-1934)
Publication Publié, 2002-12

Article révisé par les pairs

• Détails
• Contenu

Titre:	Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules.
Auteur:	Awada, Ahmad; Giacchetti, S; Gérard, B.; Eftekhary, P; Lucas, Catherine; de Valeriola, Dominique; Poullain, M G; Soudon, J; Dosquet, C; Brillanceau, M-H; Giroux, B; Marty, Marianne; Bleiberg, Harry; Calvo, F; Piccart-Gebhart, Martine
Informations sur la publication:	Annals of oncology, 13, 12, page (1925-1934)
Statut de publication:	Publié, 2002-12
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Adult
	Aged
	Biological Availability
	Carbazoles -- administration & dosage
	Carbazoles -- adverse effects
	Carbazoles -- pharmacokinetics
	Dose-Response Relationship, Drug
	Drug Administration Schedule
	Ellipticines
	Female
	Follow-Up Studies
	Humans
	Infusions, Intravenous
	Male
	Maximum Tolerated Dose
	Middle Aged
	Neoplasms -- drug therapy
	Neoplasms -- pathology
	Pyridines -- administration & dosage
	Pyridines -- adverse effects
	Pyridines -- pharmacokinetics
	Risk Assessment
	Sensitivity and Specificity
	Treatment Outcome
Note générale:	Clinical Trial
	Clinical Trial, Phase I
	Journal Article
	Multicenter Study
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:doi/10.1093/annonc/mdf321
	info:scp/0036920041
	info:pmid/12453862